NanoViricides is trading 7.03% higher at $1.37, with its October 5 Phase II Ebola trial update a possible catalyst; a direct link to the move is unconfirmed. - Enrollment began in late September, and the trial is proceeding as designed. - The release provided trial details but no efficacy results. - The Nasdaq rose 0.56% and the S&P 500 gained 0.19%; the market context does not establish a clear explanation.